Biotechnology firm Transgenomic, Inc. (TBIO.OB, TBIO) Monday said it is collaborating with Amgen Inc. (AMGN) to develop a CE-IVD test to screen patients with metastatic colorectal cancer for RAS mutations. These RAS mutations, identified using the CE-IVD CRC RAScan kits which use Surveyor-Wave technology, provide physicians with important information regarding tumor mutation status to inform clinical treatment decisions for their mCRC patients, added the company. Financial terms of the agreement were not disclosed.
Commenting on the development, Craig Tuttle, Chief Executive Officer of Transgenomic said, "This collaboration with Amgen is indicative of how Transgenomic's proprietary molecular technologies are advancing personalized medicine...This highly precise, innovative test was developed at Transgenomic's laboratories, which excel in genomic and genetic analysis, novel technology development, and its application in clinical research and trials."
For comments and feedback: editorial@rttnews.com